CNS Stimulant Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Central Nervous System (CNS) Stimulant Drugs Market Analysis

The Central Nervous System Stimulant Drugs Market size is estimated at USD 11.01 billion in 2024, and is expected to reach USD 15.01 billion by 2029, growing at a CAGR of 6.39% during the forecast period (2024-2029).

• The significant factor attributing to this market's growth is CNS disorders such as sleep apnea, narcolepsy, and attention deficit hyperactivity disorder, which have witnessed a substantial rise in recent years. According to a study published in the American Thoracic Society in 2022, obstructive sleep apnea (OSA) has a global prevalence of over 22.6%. The expanding senior population significantly impacts the CNS stimulant drugs market. The aged individual has a high risk of developing central nervous system issues such as sleeping disorders and ADHD, which require CNS stimulant drugs for their effective management. Over 20% of the elderly population have a state of sleep apnea and daytime sleepiness.
• For instance, according to Sleep Care Online, the shape of sleep apnea in elderly patients aggravates the pre-existing medical conditions common in older patients, including hypertension, cardiovascular issues, and diabetes. For instance, according to the data published by the World Health Organization in October 2022, it is estimated that by 2030, 1 in 6 people worldwide will be aged 60 years or over. The share of the population aged 60 years and over will increase to 1.4 billion in 2030; by 2050, the number of people aged 60 years and older will double to 2.1 billion. It was also estimated that the number of persons aged 80 years or older is expected to triple by 2050 to reach 426 million.
• According to the January 2023 World Social Report, the number of adults aged 65 and older is expected to more than quadruple between 2021 and 2050, increasing from 761 million to 1.6 billion. The number of people aged 80 years or older is growing even faster. Thus, the expanding geriatric population is anticipated to boost the demand for CNS stimulant drugs, which will boost the growth of the market in the coming years.
• The strategic activities taken by the market players, such as product launches, mergers, and acquisitions, are expected to contribute to market growth during the forecast period. For instance, in August 2022, Tris Pharma Inc. launched its Dyanavel XR, which is an amphetamine extended-release tablet intended for oral use for the treatment of attention deficit hyperactivity disorder.
• Therefore, owing to the factors above, the market is anticipated to grow during the forecast period. However, numerous side effects of drugs are expected to hinder the market's growth during the forecast period.

Central Nervous System (CNS) Stimulant Drugs Market Trends

The Attention Deficit Hyperactivity Disorder Segment is Expected to Witness Significant Growth During the Forecast Period

Central Nervous System (CNS) Stimulant Drugs Industry Segmentation

A central nervous system (CNS) stimulant is a drug that enhances the levels of specific compounds in the brain and encourages alertness, attention, energy, and physical activity.

The central nervous system (CNS) stimulant drugs market is segmented by product type, application, and geography. By product type, the market is segmented into lisdexamfetamine, dextroamphetamine, methylphenidate HCL, and other product types. By application, the market is segmented as attention deficit hyperactivity disorder (ADHD), sleeping disorder, and other applications. The market is segmented by geography, such as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally.

The report offers the value (in USD) for the above segments.